Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Receivables (2016 - 2025)

Arcadia Biosciences' Receivables history spans 12 years, with the latest figure at $425000.0 for Q4 2025.

  • For Q4 2025, Receivables fell 63.83% year-over-year to $425000.0; the TTM value through Dec 2025 reached $425000.0, down 63.83%, while the annual FY2025 figure was $425000.0, 63.83% down from the prior year.
  • Receivables reached $425000.0 in Q4 2025 per RKDA's latest filing, down from $831000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $3.9 million in Q2 2022 to a low of $304000.0 in Q3 2023.
  • Average Receivables over 5 years is $1.3 million, with a median of $1.1 million recorded in 2021.
  • Peak YoY movement for Receivables: surged 289.54% in 2021, then plummeted 88.85% in 2023.
  • A 5-year view of Receivables shows it stood at $1.4 million in 2021, then decreased by 12.41% to $1.2 million in 2022, then plummeted by 57.83% to $506000.0 in 2023, then surged by 132.21% to $1.2 million in 2024, then crashed by 63.83% to $425000.0 in 2025.
  • Per Business Quant, the three most recent readings for RKDA's Receivables are $425000.0 (Q4 2025), $831000.0 (Q3 2025), and $1.3 million (Q2 2025).